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In this issue of the Journal, Delva et al. discuss in a Viewpoint
our Perspective article published in the New England Journal
of Medicine in which we argue for the urgent need for a
clinical trial on when to initiate antiretroviral therapy (ART) in
HIV-infected patients in sub-Saharan Africa [1]. The authors
posit that there is currently sufficient evidence to make
informed decisions regarding this issue and consequently
individual patients’ autonomy should be the key factor in
determining the timing for ART initiation.
As readers can review our Perspective article, we will not
repeat arguments concerning the lack of definitive evidence
to guide ART initiation, the limited evidence from observa-
tional studies nor the limitations of ongoing studies assessing
timing for initiation of ART for African settings. Nonetheless,
a few points that directly relate to the Viewpoint authors’
arguments are important to address.
With regard to the observational studies the authors
cite as evidence in support of early initiation of ART, two
of the articles do not provide relevant information to the
question of early versus deferred ART [2,3] and the other
two are focused on the use of ART in individuals with early
or acute HIV infection [4,5]. Recently, Sabin et al. carefully
reviewed the available observational studies related to early
versus deferred ART initiation and highlighted the in-
consistent estimates of benefit particularly with regard to
mortality, the modest effect size noted with early ART
use and the risk of confounding inherent to observational
studies [6].
Another argument that the authors present is that the use
of early ART is associated with a protective effect against
tuberculosis. However, it is important to note that the
majority of available evidence thus far is based on the use
of ART in patients with advanced HIV disease [7]. In addition,
the meta-analysis cited by the Viewpoint’s authors included a
limited number of individuals who initiated ART in the higher
CD4 cell count strata, mostly derived from observational
studies [8]. HPTN 052, the sole randomized study included in
the former meta-analysis with relevant patient population,
did not demonstrate a statistically significant reduction in the
incidence of pulmonary tuberculosis, even though the control
group initiated ART well below the advised CD4 cell count
threshold of 350 cell/mm3 [9]. We believe that clarification
and quantification of the preventive benefit of early ART on
tuberculosis incidence is a strong argument for the clinical
trial we propose.
The authors argue that diversity in guidelines and practice
internationally mainly reflects differences in financial re-
sources available across regions, rather than the absence of
definitive evidence. We disagree with this position; the
attitudes and practices in the United Kingdom and other
parts of Europe, for example, where therapy upon early
diagnosis is not recommended, differ from those in the
United States, but the reasons relate to different interpreta-
tions of the evidence and different approaches to care, rather
than primarily financial considerations [10].
The authors state that clinical trials are most appropriate
for investigating efficacy and safety of new regimens, and are
not of relevance to strategy questions that can inform
guidelines. This overlooks the many clinical trials that com-
pared various strategies rather than new drug regimens and
that have had profound impact on guidelines and clinical
practice. Relevant examples include HPTN 052, the SMART
study, the SAPIT tuberculosis trial and the CIPRA 001 Haiti
trial [9,1113]. In the realm of HIV prevention, large-scale
randomized clinical trials are planned to provide a definitive
answer as to whether the efficacy of treatment as prevention
demonstrated in HPTN 052 will be realized at a population
level [14]. We believe that a parallel trial is needed to answer
the question with regard to the balance of benefits and risks
for those with early HIV disease who would need to be
treated [15].
There are compelling reasons to believe that early use of
ARTmay best prevent adverse consequences of HIV infection.
However, guidelines should be based as much as possible on
firm evidence rather than expert opinion, especially when
applied to millions of people and necessitating billions of
dollars of funding. While the World Health Organization has
released new guidelines that recommend initiation of ART in
adults at CD4 cell count of B500 cell/mm3, the guideline
document itself states that ‘‘further research is required to
determine more fully the clinical benefits and disadvantages
of earlier ART initiation’’ [16]. Thus, even as guidelines
change based on limited evidence, this should not stop the
quest for definitive answers to critical clinical questions.
The Viewpoint pits patient autonomy versus clinical trials as
reflected in the title. In contrast, we believe that clinical trials
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are necessary to provide the best quality evidence that would
inform clinical guidelines and enable clinicians and patients
to make informed decisions. We are struck that the indi-
vidual approach advocated by the authors, with each patient/
clinician making an independent decision based on incom-
plete evidence, is the antithesis of the public health approach
promoted by the World Health Organization which has been
the foundation of ART scale-up and perhaps the key factor
allowing for successful access to ART to more than 9 million
people globally, the majority in Africa [17].
Health is both a personal right and responsibility, and no
one should take medicines against his or her will. However,
consistent advice based on the strongest evidence is an
essential requirement for program implementation and as-
surance of accountability, and is fundamental to informed
and empowered patients.
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